カテゴリー： QYResearch, 世界, 医療/バイオ

世界の婦人科がん診断市場インサイト及び予測（遺伝カウンセリング検査、がんリスク検査、キット検査）

◆英語タイトル：Global Gynecological Cancer Diagnostics Market Insights, Forecast to 2028
	◆商品コード：QY22JLX09495 ◆発行会社（リサーチ会社）：QYResearch ◆発行日：2022年7月（※2025年版があります。お問い合わせください。） ◆ページ数：105 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（受注後3営業日） ◆調査対象地域：グローバル ◆産業分野：医療機器

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD4,900 ⇒換算￥744,800	見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）	USD7,350 ⇒換算￥1,117,200	見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）	USD9,800 ⇒換算￥1,489,600	見積依頼/購入/質問フォーム

★QYResearchに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

COVID-19のパンデミックにより、婦人科がん診断のグローバル市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に婦人科がん診断の世界市場のxxx％を占める「遺伝カウンセリング検査」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「妊娠性絨毛性疾患診断」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。
婦人科がん診断の中国市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパの婦人科がん診断市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。

婦人科がん診断のグローバル主要企業には、UT Southwestern、Abramson Cancer Center、Northwestern Medicine、Sysmex Europe SE、Fujirebio、Premier Health、Agilent Technologies, Inc、ARUP Laboratories、CENTOGENE、F. Hoffmann-La Roche Ltd、Fulgent Genetics, Inc、Invitae Corporation、Myriad Genetics, Inc、BGI Groupなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。

婦人科がん診断市場は、種類と用途によって区分されます。世界の婦人科がん診断市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。

【種類別セグメント】
遺伝カウンセリング検査、がんリスク検査、キット検査

【用途別セグメント】
妊娠性絨毛性疾患診断、子宮内膜がん診断、腹膜がん診断、子宮頸がん診断、卵巣がん診断、膣がん診断、子宮がん診断、外陰部がん診断

【掲載地域】
北米：アメリカ、カナダ
ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米：メキシコ、ブラジル、アルゼンチン
中東・アフリカ：トルコ、サウジアラビア、UAE

【目次（一部）】

・調査の範囲
- 婦人科がん診断製品概要
- 種類別市場（遺伝カウンセリング検査、がんリスク検査、キット検査）
- 用途別市場（妊娠性絨毛性疾患診断、子宮内膜がん診断、腹膜がん診断、子宮頸がん診断、卵巣がん診断、膣がん診断、子宮がん診断、外陰部がん診断）
- 調査の目的
・エグゼクティブサマリー
- 世界の婦人科がん診断販売量予測2017-2028
- 世界の婦人科がん診断売上予測2017-2028
- 婦人科がん診断の地域別販売量
- 婦人科がん診断の地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別婦人科がん診断販売量
- 主要メーカー別婦人科がん診断売上
- 主要メーカー別婦人科がん診断価格
- 競争状況の分析
- 企業M&A動向
・種類別市場規模（遺伝カウンセリング検査、がんリスク検査、キット検査）
- 婦人科がん診断の種類別販売量
- 婦人科がん診断の種類別売上
- 婦人科がん診断の種類別価格
・用途別市場規模（妊娠性絨毛性疾患診断、子宮内膜がん診断、腹膜がん診断、子宮頸がん診断、卵巣がん診断、膣がん診断、子宮がん診断、外陰部がん診断）
- 婦人科がん診断の用途別販売量
- 婦人科がん診断の用途別売上
- 婦人科がん診断の用途別価格
・北米市場
- 北米の婦人科がん診断市場規模（種類別、用途別）
- 主要国別の婦人科がん診断市場規模（アメリカ、カナダ）
・ヨーロッパ市場
- ヨーロッパの婦人科がん診断市場規模（種類別、用途別）
- 主要国別の婦人科がん診断市場規模（ドイツ、フランス、イギリス、イタリア、ロシア）
・アジア太平洋市場
- アジア太平洋の婦人科がん診断市場規模（種類別、用途別）
- 主要国別の婦人科がん診断市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア）
・中南米市場
- 中南米の婦人科がん診断市場規模（種類別、用途別）
- 主要国別の婦人科がん診断市場規模（メキシコ、ブラジル、アルゼンチン）
・中東・アフリカ市場
- 中東・アフリカの婦人科がん診断市場規模（種類別、用途別）
- 主要国別の婦人科がん診断市場規模（トルコ、サウジアラビア）
・企業情報
UT Southwestern、Abramson Cancer Center、Northwestern Medicine、Sysmex Europe SE、Fujirebio、Premier Health、Agilent Technologies, Inc、ARUP Laboratories、CENTOGENE、F. Hoffmann-La Roche Ltd、Fulgent Genetics, Inc、Invitae Corporation、Myriad Genetics, Inc、BGI Group
・産業チェーン及び販売チャネル分析
- 婦人科がん診断の産業チェーン分析
- 婦人科がん診断の原材料
- 婦人科がん診断の生産プロセス
- 婦人科がん診断の販売及びマーケティング
- 婦人科がん診断の主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- 婦人科がん診断の産業動向
- 婦人科がん診断のマーケットドライバー
- 婦人科がん診断の課題
- 婦人科がん診断の阻害要因
・主な調査結果

Market Analysis and Insights: Global Gynecological Cancer Diagnostics Market
The global Gynecological Cancer Diagnostics market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Genetic Counseling Test accounting for % of the Gynecological Cancer Diagnostics global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Gestational Trophoblastic Disease Diagnostics segment is altered to an % CAGR throughout this forecast period.
China Gynecological Cancer Diagnostics market size is valued at US$ million in 2021, while the North America and Europe Gynecological Cancer Diagnostics are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Gynecological Cancer Diagnostics landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Gynecological Cancer Diagnostics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Gynecological Cancer Diagnostics market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Gynecological Cancer Diagnostics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Gynecological Cancer Diagnostics market.
Global Gynecological Cancer Diagnostics Scope and Market Size
Gynecological Cancer Diagnostics market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Gynecological Cancer Diagnostics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Genetic Counseling Test
Cancer Risk Test
Kits Test
Segment by Application
Gestational Trophoblastic Disease Diagnostics
Endometrial Cancer Diagnostics
Peritoneal Cancer Diagnostics
Cervical Cancer Diagnostics
Ovarian Cancer Diagnostics
Vaginal Cancer Diagnostics
Uterine Cancer Diagnostics
Vulvar Cancer Diagnostics
By Company
UT Southwestern
Abramson Cancer Center
Northwestern Medicine
Sysmex Europe SE
Fujirebio
Premier Health
Agilent Technologies, Inc
ARUP Laboratories
CENTOGENE
F. Hoffmann-La Roche Ltd
Fulgent Genetics, Inc
Invitae Corporation
Myriad Genetics, Inc
BGI Group
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

❖ レポートの目次 ❖

1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Gynecological Cancer Diagnostics Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Genetic Counseling Test
1.2.3 Cancer Risk Test
1.2.4 Kits Test
1.3 Market by Application
1.3.1 Global Gynecological Cancer Diagnostics Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Gestational Trophoblastic Disease Diagnostics
1.3.3 Endometrial Cancer Diagnostics
1.3.4 Peritoneal Cancer Diagnostics
1.3.5 Cervical Cancer Diagnostics
1.3.6 Ovarian Cancer Diagnostics
1.3.7 Vaginal Cancer Diagnostics
1.3.8 Uterine Cancer Diagnostics
1.3.9 Vulvar Cancer Diagnostics
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Gynecological Cancer Diagnostics Market Perspective (2017-2028)
2.2 Gynecological Cancer Diagnostics Growth Trends by Region
2.2.1 Gynecological Cancer Diagnostics Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Gynecological Cancer Diagnostics Historic Market Size by Region (2017-2022)
2.2.3 Gynecological Cancer Diagnostics Forecasted Market Size by Region (2023-2028)
2.3 Gynecological Cancer Diagnostics Market Dynamics
2.3.1 Gynecological Cancer Diagnostics Industry Trends
2.3.2 Gynecological Cancer Diagnostics Market Drivers
2.3.3 Gynecological Cancer Diagnostics Market Challenges
2.3.4 Gynecological Cancer Diagnostics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Gynecological Cancer Diagnostics Players by Revenue
3.1.1 Global Top Gynecological Cancer Diagnostics Players by Revenue (2017-2022)
3.1.2 Global Gynecological Cancer Diagnostics Revenue Market Share by Players (2017-2022)
3.2 Global Gynecological Cancer Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Gynecological Cancer Diagnostics Revenue
3.4 Global Gynecological Cancer Diagnostics Market Concentration Ratio
3.4.1 Global Gynecological Cancer Diagnostics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Gynecological Cancer Diagnostics Revenue in 2021
3.5 Gynecological Cancer Diagnostics Key Players Head office and Area Served
3.6 Key Players Gynecological Cancer Diagnostics Product Solution and Service
3.7 Date of Enter into Gynecological Cancer Diagnostics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Gynecological Cancer Diagnostics Breakdown Data by Type
4.1 Global Gynecological Cancer Diagnostics Historic Market Size by Type (2017-2022)
4.2 Global Gynecological Cancer Diagnostics Forecasted Market Size by Type (2023-2028)
5 Gynecological Cancer Diagnostics Breakdown Data by Application
5.1 Global Gynecological Cancer Diagnostics Historic Market Size by Application (2017-2022)
5.2 Global Gynecological Cancer Diagnostics Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Gynecological Cancer Diagnostics Market Size (2017-2028)
6.2 North America Gynecological Cancer Diagnostics Market Size by Type
6.2.1 North America Gynecological Cancer Diagnostics Market Size by Type (2017-2022)
6.2.2 North America Gynecological Cancer Diagnostics Market Size by Type (2023-2028)
6.2.3 North America Gynecological Cancer Diagnostics Market Share by Type (2017-2028)
6.3 North America Gynecological Cancer Diagnostics Market Size by Application
6.3.1 North America Gynecological Cancer Diagnostics Market Size by Application (2017-2022)
6.3.2 North America Gynecological Cancer Diagnostics Market Size by Application (2023-2028)
6.3.3 North America Gynecological Cancer Diagnostics Market Share by Application (2017-2028)
6.4 North America Gynecological Cancer Diagnostics Market Size by Country
6.4.1 North America Gynecological Cancer Diagnostics Market Size by Country (2017-2022)
6.4.2 North America Gynecological Cancer Diagnostics Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Gynecological Cancer Diagnostics Market Size (2017-2028)
7.2 Europe Gynecological Cancer Diagnostics Market Size by Type
7.2.1 Europe Gynecological Cancer Diagnostics Market Size by Type (2017-2022)
7.2.2 Europe Gynecological Cancer Diagnostics Market Size by Type (2023-2028)
7.2.3 Europe Gynecological Cancer Diagnostics Market Share by Type (2017-2028)
7.3 Europe Gynecological Cancer Diagnostics Market Size by Application
7.3.1 Europe Gynecological Cancer Diagnostics Market Size by Application (2017-2022)
7.3.2 Europe Gynecological Cancer Diagnostics Market Size by Application (2023-2028)
7.3.3 Europe Gynecological Cancer Diagnostics Market Share by Application (2017-2028)
7.4 Europe Gynecological Cancer Diagnostics Market Size by Country
7.4.1 Europe Gynecological Cancer Diagnostics Market Size by Country (2017-2022)
7.4.2 Europe Gynecological Cancer Diagnostics Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Gynecological Cancer Diagnostics Market Size (2017-2028)
8.2 Asia-Pacific Gynecological Cancer Diagnostics Market Size by Type
8.2.1 Asia-Pacific Gynecological Cancer Diagnostics Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Gynecological Cancer Diagnostics Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Gynecological Cancer Diagnostics Market Share by Type (2017-2028)
8.3 Asia-Pacific Gynecological Cancer Diagnostics Market Size by Application
8.3.1 Asia-Pacific Gynecological Cancer Diagnostics Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Gynecological Cancer Diagnostics Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Gynecological Cancer Diagnostics Market Share by Application (2017-2028)
8.4 Asia-Pacific Gynecological Cancer Diagnostics Market Size by Region
8.4.1 Asia-Pacific Gynecological Cancer Diagnostics Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Gynecological Cancer Diagnostics Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Gynecological Cancer Diagnostics Market Size (2017-2028)
9.2 Latin America Gynecological Cancer Diagnostics Market Size by Type
9.2.1 Latin America Gynecological Cancer Diagnostics Market Size by Type (2017-2022)
9.2.2 Latin America Gynecological Cancer Diagnostics Market Size by Type (2023-2028)
9.2.3 Latin America Gynecological Cancer Diagnostics Market Share by Type (2017-2028)
9.3 Latin America Gynecological Cancer Diagnostics Market Size by Application
9.3.1 Latin America Gynecological Cancer Diagnostics Market Size by Application (2017-2022)
9.3.2 Latin America Gynecological Cancer Diagnostics Market Size by Application (2023-2028)
9.3.3 Latin America Gynecological Cancer Diagnostics Market Share by Application (2017-2028)
9.4 Latin America Gynecological Cancer Diagnostics Market Size by Country
9.4.1 Latin America Gynecological Cancer Diagnostics Market Size by Country (2017-2022)
9.4.2 Latin America Gynecological Cancer Diagnostics Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Gynecological Cancer Diagnostics Market Size (2017-2028)
10.2 Middle East & Africa Gynecological Cancer Diagnostics Market Size by Type
10.2.1 Middle East & Africa Gynecological Cancer Diagnostics Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Gynecological Cancer Diagnostics Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Gynecological Cancer Diagnostics Market Share by Type (2017-2028)
10.3 Middle East & Africa Gynecological Cancer Diagnostics Market Size by Application
10.3.1 Middle East & Africa Gynecological Cancer Diagnostics Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Gynecological Cancer Diagnostics Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Gynecological Cancer Diagnostics Market Share by Application (2017-2028)
10.4 Middle East & Africa Gynecological Cancer Diagnostics Market Size by Country
10.4.1 Middle East & Africa Gynecological Cancer Diagnostics Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Gynecological Cancer Diagnostics Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 UT Southwestern
11.1.1 UT Southwestern Company Details
11.1.2 UT Southwestern Business Overview
11.1.3 UT Southwestern Gynecological Cancer Diagnostics Introduction
11.1.4 UT Southwestern Revenue in Gynecological Cancer Diagnostics Business (2017-2022)
11.1.5 UT Southwestern Recent Developments
11.2 Abramson Cancer Center
11.2.1 Abramson Cancer Center Company Details
11.2.2 Abramson Cancer Center Business Overview
11.2.3 Abramson Cancer Center Gynecological Cancer Diagnostics Introduction
11.2.4 Abramson Cancer Center Revenue in Gynecological Cancer Diagnostics Business (2017-2022)
11.2.5 Abramson Cancer Center Recent Developments
11.3 Northwestern Medicine
11.3.1 Northwestern Medicine Company Details
11.3.2 Northwestern Medicine Business Overview
11.3.3 Northwestern Medicine Gynecological Cancer Diagnostics Introduction
11.3.4 Northwestern Medicine Revenue in Gynecological Cancer Diagnostics Business (2017-2022)
11.3.5 Northwestern Medicine Recent Developments
11.4 Sysmex Europe SE
11.4.1 Sysmex Europe SE Company Details
11.4.2 Sysmex Europe SE Business Overview
11.4.3 Sysmex Europe SE Gynecological Cancer Diagnostics Introduction
11.4.4 Sysmex Europe SE Revenue in Gynecological Cancer Diagnostics Business (2017-2022)
11.4.5 Sysmex Europe SE Recent Developments
11.5 Fujirebio
11.5.1 Fujirebio Company Details
11.5.2 Fujirebio Business Overview
11.5.3 Fujirebio Gynecological Cancer Diagnostics Introduction
11.5.4 Fujirebio Revenue in Gynecological Cancer Diagnostics Business (2017-2022)
11.5.5 Fujirebio Recent Developments
11.6 Premier Health
11.6.1 Premier Health Company Details
11.6.2 Premier Health Business Overview
11.6.3 Premier Health Gynecological Cancer Diagnostics Introduction
11.6.4 Premier Health Revenue in Gynecological Cancer Diagnostics Business (2017-2022)
11.6.5 Premier Health Recent Developments
11.7 Agilent Technologies, Inc
11.7.1 Agilent Technologies, Inc Company Details
11.7.2 Agilent Technologies, Inc Business Overview
11.7.3 Agilent Technologies, Inc Gynecological Cancer Diagnostics Introduction
11.7.4 Agilent Technologies, Inc Revenue in Gynecological Cancer Diagnostics Business (2017-2022)
11.7.5 Agilent Technologies, Inc Recent Developments
11.8 ARUP Laboratories
11.8.1 ARUP Laboratories Company Details
11.8.2 ARUP Laboratories Business Overview
11.8.3 ARUP Laboratories Gynecological Cancer Diagnostics Introduction
11.8.4 ARUP Laboratories Revenue in Gynecological Cancer Diagnostics Business (2017-2022)
11.8.5 ARUP Laboratories Recent Developments
11.9 CENTOGENE
11.9.1 CENTOGENE Company Details
11.9.2 CENTOGENE Business Overview
11.9.3 CENTOGENE Gynecological Cancer Diagnostics Introduction
11.9.4 CENTOGENE Revenue in Gynecological Cancer Diagnostics Business (2017-2022)
11.9.5 CENTOGENE Recent Developments
11.10 F. Hoffmann-La Roche Ltd
11.10.1 F. Hoffmann-La Roche Ltd Company Details
11.10.2 F. Hoffmann-La Roche Ltd Business Overview
11.10.3 F. Hoffmann-La Roche Ltd Gynecological Cancer Diagnostics Introduction
11.10.4 F. Hoffmann-La Roche Ltd Revenue in Gynecological Cancer Diagnostics Business (2017-2022)
11.10.5 F. Hoffmann-La Roche Ltd Recent Developments
11.11 Fulgent Genetics, Inc
11.11.1 Fulgent Genetics, Inc Company Details
11.11.2 Fulgent Genetics, Inc Business Overview
11.11.3 Fulgent Genetics, Inc Gynecological Cancer Diagnostics Introduction
11.11.4 Fulgent Genetics, Inc Revenue in Gynecological Cancer Diagnostics Business (2017-2022)
11.11.5 Fulgent Genetics, Inc Recent Developments
11.12 Invitae Corporation
11.12.1 Invitae Corporation Company Details
11.12.2 Invitae Corporation Business Overview
11.12.3 Invitae Corporation Gynecological Cancer Diagnostics Introduction
11.12.4 Invitae Corporation Revenue in Gynecological Cancer Diagnostics Business (2017-2022)
11.12.5 Invitae Corporation Recent Developments
11.13 Myriad Genetics, Inc
11.13.1 Myriad Genetics, Inc Company Details
11.13.2 Myriad Genetics, Inc Business Overview
11.13.3 Myriad Genetics, Inc Gynecological Cancer Diagnostics Introduction
11.13.4 Myriad Genetics, Inc Revenue in Gynecological Cancer Diagnostics Business (2017-2022)
11.13.5 Myriad Genetics, Inc Recent Developments
11.14 BGI Group
11.14.1 BGI Group Company Details
11.14.2 BGI Group Business Overview
11.14.3 BGI Group Gynecological Cancer Diagnostics Introduction
11.14.4 BGI Group Revenue in Gynecological Cancer Diagnostics Business (2017-2022)
11.14.5 BGI Group Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の婦人科がん診断市場インサイト及び予測（遺伝カウンセリング検査、がんリスク検査、キット検査）(Global Gynecological Cancer Diagnostics Market Insights, Forecast to 2028)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

世界の婦人科がん診断市場インサイト及び予測（遺伝カウンセリング検査、がんリスク検査、キット検査）

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp